Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.390
-0.420 (-8.73%)
Mar 31, 2025, 1:11 PM EDT - Market open
Y-mAbs Therapeutics Revenue
In the year 2024, Y-mAbs Therapeutics had annual revenue of $87.69M with 3.38% growth. Y-mAbs Therapeutics had revenue of $26.50M in the quarter ending December 31, 2024, with 13.41% growth.
Revenue (ttm)
$87.69M
Revenue Growth
+3.38%
P/S Ratio
2.43
Revenue / Employee
$843,125
Employees
104
Market Cap
198.51M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
YMAB News
- 26 days ago - Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 4 weeks ago - Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications - GlobeNewsWire
- 5 weeks ago - Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - GlobeNewsWire
- 7 weeks ago - Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference - GlobeNewsWire
- 2 months ago - Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - GlobeNewsWire
- 2 months ago - Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
- 2 months ago - Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - GlobeNewsWire